BLA 103948 · Genzyme
Lemtrada
Alemtuzumab · Injection, Intravenous · CD52-directed Cytolytic Antibody
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
May 7, 2001
Approved uses
4
Original approval plus efficacy supplements
Registered trials
350
27 Phase 3, 30 recruiting
FAERS reports
19,365
16,665 serious, 2,947 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CYTOPENIAS, INFUSION-RELATED REACTIONS, AND INFECTIONS WARNING: CYTOPENIAS, INFUSION-RELATED REACTIONS, AND INFECTIONS See full prescribing information for complete boxed warning. Serious, including fatal, cytopenias, infusion-related reactions, and infections can occur (5.1–5.3). Limit doses to 30 mg (single) and 90 mg (cumulative weekly); higher doses increase risk of pancytopenia. ( 2.1 ) Escalate dose gradually and monitor patients during infusion. Withhold therapy for Grade 3 or 4 infusion-related reactions. ( 5.2 ) Administer prophylaxis against Pneumocystis jirovecii pneumonia (PCP) and herpes virus infections. ( 2.2 , 5.3 ) Cytopenias : Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving CAMPATH. Single doses of CAMPATH greater than 30 mg or cumulative doses...
What it is approved for
From the label in effect Nov 5, 2025.
CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). ( 1 )
Mechanism: CAMPATH binds to CD52, an antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. A proportion of bone marrow cells, including some CD34+ cells, express variable levels of CD52. The proposed mechanism of action is antibody-dependent cellular-mediated lysis following cell surface binding of CAMPATH to the leukemic cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 28, 2018 Supplement 5160 · Efficacy LabelLetter
- Nov 14, 2014 Supplement 5139 · Efficacy
- Sep 19, 2007 Supplement 5070 · Efficacy · priority review OrphanLetter
- May 7, 2001 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
3 products under this application
- LEMTRADA · ALEMTUZUMAB 12MG/1.2ML (10MG/ML) · INJECTABLE, INJECTION · Prescription
- CAMPATH · ALEMTUZUMAB 10MG/ML · VIAL, INTRAVENOUS · Prescription
- CAMPATH · ALEMTUZUMAB 30MG/ML · VIAL, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alemtuzumab" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesPivotal-lookingCompleted
The University of New South WalesAcademic, hospital or other
NCT00454480 · 2,000 participants (planned) · Start Aug 2006 · Primary completion Aug 2012
Drug: alemtuzumab; arsenic trioxide and 9 more · For: Leukemia; Myelodysplastic Syndromes
Sites: Basingstoke, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 96 sites in all
- An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00930553 · 1,314 participants · Start Aug 2009 · Primary completion Feb 2016
Drug: alemtuzumab · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Cullman, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 176 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02255656 · 1,062 participants · Start Jan 7, 2015 · Primary completion Jul 15, 2020
Drug: alemtuzumab GZ402673 · For: Relapsing Remitting Multiple Sclerosis
Sites: Cullman, Alabama; Phoenix, Arizona; Tucson, Arizona · 131 sites in all
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft NephropathyPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT01120028 · 852 participants · Start Sep 2010 · Primary completion Feb 2014
Drug: Alemtuzumab; Basiliximab and 2 more · For: Kidney Transplantation
Sites: Oxford, United Kingdom; Birmingham, United Kingdom; Cambridge, United Kingdom · 20 sites in all
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00548405 · 840 participants · Start Oct 2007 · Primary completion Sep 2011
Drug: Alemtuzumab 12 mg; Alemtuzumab 24 mg and 1 more · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Cullman, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 191 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study OnePivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00530348 · 581 participants · Start Aug 2007 · Primary completion Apr 2011
Drug: Alemtuzumab; Interferon beta-1a · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Cullman, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 101 sites in all
- Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant RecipientsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00113269 · 501 participants · Start May 2005 · Primary completion Mar 2009
Drug: basiliximab; rabbit anti-thymocyte globulin and 4 more · For: Kidney Transplantation
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 29 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache1,906
- fatigue1,874
- pyrexia1,784
- off label use1,698
- rash1,200
- nausea1,190
- drug ineffective1,032
- dyspnoea985
- asthenia942
- multiple sclerosis relapse923
- lymphocyte count decreased879
- cytomegalovirus infection839
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 153 |
| 2005 | 150 |
| 2006 | 150 |
| 2007 | 189 |
| 2008 | 336 |
| 2009 | 373 |
| 2010 | 363 |
| 2011 | 704 |
| 2012 | 320 |
| 2013 | 427 |
| 2014 | 486 |
| 2015 | 985 |
| 2016 | 1,627 |
| 2017 | 1,750 |
| 2018 | 2,274 |
| 2019 | 2,380 |
| 2020 | 1,690 |
| 2021 | 1,288 |
| 2022 | 1,072 |
| 2023 | 849 |
| 2024 | 738 |
| 2025 | 635 |
| 2026 | 425 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Lemtrada (Alemtuzumab) · HCPCS J0202
2024 spending
$2.7M
Beneficiaries
25
102 claims
Per beneficiary
$107,721
2024 ASP limit $2,339.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,586,313 |
| 2021 | $5,626,186 |
| 2022 | $4,021,632 |
| 2023 | $3,660,335 |
| 2024 | $2,693,035 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA, Drudge C, Walsh S, et al. · J Comp Eff Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.
Chiesa R, Georgiadis C, Rashed H, et al. · N Engl J Med 2026 · Clinical Trial, Phase I
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- [Chronic neutrophilic leukemia/chronic eosinophilic leukemia].
Kawashima I, Kirito K · Rinsho Ketsueki 2023 · Clinical Trial, Phase II, English Abstract
- Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia.
Ottaviano G, Georgiadis C, Gkazi SA, et al. · Sci Transl Med 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Sanofi · Also marketed as Campath
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.